5-FU for genital warts in non-immunocompromised individuals

Batista, Claudio S; Atallah, Álvaro Nagib; Saconato, Humberto; Silva, Edina MK da

doi:10.1002/14651858.cd006562.pub2

Cited by 26 publications

(28 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A Cochrane review concluded that it is superior to placebo in achieving wart clearance but the authors state that the evidence provided by the current studies is weak. 83 It cannot be recommended for first-line use, but may be considered when other treatments have failed.…”

Section: Treatmentsmentioning

confidence: 99%

2019 IUSTI‐Europe guideline for the management of anogenital warts

Gilson

Nugent

Werner

et al. 2020

Acad Dermatol Venereol

105

View full text Add to dashboard Cite

This guideline is an update of the 2011 European Guideline for the Management of Anogenital Warts. It is intended to support best practice in the care of patients with anogenital warts by including evidence-based recommendations on diagnosis, treatment, follow-up and advice to patients. It is intended for use by healthcare professionals in sexual healthcare or dermato-venereology clinics in Europe but may be adapted for use in other settings where the management of anogenital warts is undertaken. As a European guideline, recommendations should be adapted according to national circumstances and healthcare systems. Despite the availability of vaccine to prevent HPV types 6 and 11, the cause of >95% anogenital warts, they remain an important and frequent health problem. The previous systematic review of randomized controlled trials for anogenital warts was updated. The changes in the present guideline include the following: Updated background information on the prevalence, natural history and transmission of human papillomavirus (HPV) infection and anogenital warts. Key recommendations for diagnosis and treatment have been graded according to the strength of the recommendation and the quality of supporting evidence. 5-fluorouracil, local interferon and photodynamic therapy have been evaluated and included as potential second-line treatment options. Evidence of the impact of HPV vaccination on the incidence of anogenital warts has been updated.

show abstract

Section: Treatmentsmentioning

confidence: 99%

2019 IUSTI‐Europe guideline for the management of anogenital warts

Gilson

Nugent

Werner

et al. 2020

Acad Dermatol Venereol

105

View full text Add to dashboard Cite

show abstract

“…A great number of reports have described good result with topical therapies: monochloracetic, bichloroacetic, and trichloroacetic acids, lactic, formic or salicylic acids; squaric acid dibutyl ester; imiquimod, fluorouracil or zinc sulphate; cidofovir; cryotherapy; cantharidin, surgical curettage, photodynamic therapy, and pulsed-dye or carbon dioxide laser (1,2). Systemic administration of cimetidine, levamisole, hydroxychloroquine, oral isotretinoin have been proven to be effective in recalcitrant warts (1,3).…”

Section: Discussionmentioning

confidence: 99%

Topical malic acid in combination with citric acid: an option to treat recalcitrant warts

Chiriac¹,

Brzeziński²

2015

Dermatologic Therapy

View full text Add to dashboard Cite

A 42-year old man, construction worker, in good health state, seeks for dermatological advice and treatment, for numerous cutaneous warts distributed on dorsal aspects of both hands. The first lesion was observed 2 years before present consultation. Over time the number of warts has increased despite many attempts of therapy: salicilic acid, cryotherapy, surgical curretage, 5% imiquimod cream, and homeotherapy (FIG.

show abstract

“…Seventy one percent of patients treated with 5-FU had complete resolution of their anogenital warts versus 23% of patients treated with placebo. One of those studies reported a recurrence of lesions in one patient who originally had complete resolution [44]. 5-FU can be administered as a topical gel or by intralesional injection.…”

Section: Antimitotic Therapymentioning

confidence: 99%

Advancements in Pharmacotherapy for Noncancerous Manifestations of HPV

Kollipara

Ekhlassi

Downing

et al. 2015

JCM

View full text Add to dashboard Cite

Human papillomavirus (HPV) is the most common sexually transmitted disease. Via infection of the basal epithelial cells, HPV causes numerous malignancies and noncancerous cutaneous manifestations. Noncancerous cutaneous manifestations of HPV, including common, plantar, plane, and anogenital warts, are among the most common reasons for an office visit. Although there are various therapies available, they are notoriously difficult to treat. HPV treatments can be grouped into destructive (cantharidin, salicylic acid), virucidal (cidofovir, interferon-α), antimitotic (bleomycin, podophyllotoxin, 5-fluorouracil), immunotherapy (Candida antigen, contact allergen immunotherapy, imiquimod) or miscellaneous (trichloroacetic acid, polyphenon E). The mechanism of action, recent efficacy data, safety profile and recommended regimen for each of these treatment modalities is discussed.

show abstract

5-FU for genital warts in non-immunocompromised individuals

Cited by 26 publications

References 48 publications

2019 IUSTI‐Europe guideline for the management of anogenital warts

2019 IUSTI‐Europe guideline for the management of anogenital warts

Topical malic acid in combination with citric acid: an option to treat recalcitrant warts

Advancements in Pharmacotherapy for Noncancerous Manifestations of HPV

Contact Info

Product

Resources

About